| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV.PHARMTOX.011008.145613 |
| P698 | PubMed publication ID | 18851702 |
| P2093 | author name string | Lawrence J Lesko | |
| Jogarao V S Gobburu | |||
| P304 | page(s) | 291-301 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Quantitative disease, drug, and trial models | |
| P478 | volume | 49 |
| Q45916380 | A New Population-Enrichment Strategy to Improve Efficiency of Placebo-Controlled Clinical Trials of Antidepressant Drugs |
| Q91873501 | A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials |
| Q27028010 | Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity |
| Q92447843 | An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate |
| Q53356299 | An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. |
| Q41021058 | Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model |
| Q29013931 | Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development |
| Q35595794 | Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development |
| Q37523221 | Biomarkers in clinical drug development |
| Q33717140 | Challenges in conducting clinical trials in children: approaches for improving performance |
| Q38905356 | Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention |
| Q86567599 | Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation |
| Q85225004 | Clinical pharmacology and viral infections |
| Q35555963 | Clinical trials in the era of personalized oncology |
| Q45347575 | Confirmatory analysis for phase III population pharmacokinetics |
| Q43480141 | Development of a placebo effect model combined with a dropout model for bipolar disorder |
| Q41639443 | Disease Progression Modeling: Key Concepts and Recent Developments |
| Q64101563 | Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation |
| Q38992758 | Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. |
| Q43569207 | Exposure-response modeling of anti-depressant treatments: the confounding role of placebo effect |
| Q46697094 | From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework |
| Q36080108 | Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques |
| Q39064765 | Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV. |
| Q37769100 | Improving productivity with model-based drug development: an enterprise perspective |
| Q34082039 | Knowledge management for efficient quantitative analyses during regulatory reviews |
| Q47663303 | Mathematical modeling of efficacy and safety for anticancer drugs clinical development |
| Q39639283 | Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma |
| Q38187157 | Methods for pharmacokinetic analysis in young children |
| Q39959170 | Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity |
| Q36910615 | Modeling NSCLC progression: recent advances and opportunities available |
| Q35579519 | Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats |
| Q33925036 | Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment |
| Q27010366 | Modelling and simulation as research tools in paediatric drug development |
| Q38012237 | Models for disease progression: new approaches and uses |
| Q39828343 | Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry |
| Q36052870 | Molecular mechanism matters: Benefits of mechanistic computational models for drug development. |
| Q37096317 | Moving from basic toward systems pharmacodynamic models |
| Q37763515 | Next-generation model-based drug discovery and development: quantitative and systems pharmacology |
| Q30850701 | Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiative |
| Q43772541 | Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development |
| Q38771635 | Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans |
| Q39828337 | Pharmacometrics 2020 |
| Q39828349 | Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. |
| Q49171317 | Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. |
| Q38131563 | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates |
| Q26764870 | Recent developments in using mechanistic cardiac modelling for drug safety evaluation |
| Q50708105 | Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone. |
| Q37886138 | Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. |
| Q51570078 | Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. |
| Q35003829 | The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases |
| Q85111375 | The Need for Modeling and Simulation to Design Clinical Investigations in Children |
| Q38028538 | The current role of model-based drug development. |
| Q39265454 | The paradox of scientific excellence and the search for productivity in pharmaceutical research and development |
| Q48820679 | The rise of systems pharmacology in drug discovery and development |
| Q26866417 | The role of concentration-effect relationships in the assessment of QTc interval prolongation |
Search more.